Published in Mayo Clin Proc on June 09, 2016
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI2D) | NCT00006305
Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases. Visc Med (2016) 0.75
Impact of overweight and obesity on acute exacerbations of COPD - subgroup analysis of the Taiwan Obstructive Lung Disease cohort. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA (2013) 18.86
Leptin and the regulation of body weight in mammals. Nature (1998) 14.84
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Adipose tissue as an endocrine organ. Mol Cell Endocrinol (2009) 5.20
Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol (2003) 4.86
The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. Am J Public Health (2013) 4.37
Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation (2001) 3.57
Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation (2006) 2.89
Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation (2003) 2.77
Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J (2006) 2.47
Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis (2013) 2.33
A comprehensive examination of health conditions associated with obesity in older adults. Am J Prev Med (2004) 1.89
Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med (2008) 1.84
The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorldJournal (2007) 1.81
Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J (2006) 1.73
Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol (2004) 1.64
Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol (2014) 1.61
Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med (2007) 1.57
Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: the Heart and Soul Study. Atherosclerosis (2010) 1.43
Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol (2009) 1.39
Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab (2008) 1.37
Adipokines: a link between obesity and cardiovascular disease. J Cardiol (2013) 1.29
Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care (2003) 1.27
Adipocytokines in relation to cardiovascular disease. Metabolism (2013) 1.24
Association of adiponectin with mortality in older adults: the Health, Aging, and Body Composition Study. Diabetologia (2009) 1.19
A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care (2002) 1.14
Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab (2006) 1.11
Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism (2014) 1.10
Leptin receptor and functional effects of leptin in human endothelial progenitor cells. Atherosclerosis (2005) 1.05
Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci (2013) 0.98
Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis (2011) 0.97
Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol (2012) 0.95
Leptin and vascular function: Friend or foe? Eur Heart J (2006) 0.90
Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) (2008) 0.87
Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. Am J Kidney Dis (2015) 0.83
Differential effects of leptin on adiponectin expression with weight gain versus obesity. Int J Obes (Lond) (2015) 0.81
Inhibition of leptin-induced vascular extracellular matrix remodelling by adiponectin. J Mol Endocrinol (2014) 0.78
Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. Eur J Prev Cardiol (2014) 0.77
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial†. Eur J Cardiothorac Surg (2015) 2.00
Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. J Am Coll Cardiol (2013) 1.55
Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). Am J Cardiol (2009) 1.42
The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am Heart J (2010) 1.21
Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2012) 1.04
Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). Am J Cardiol (2009) 0.97
Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study. Mayo Clin Proc (2010) 0.92
Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial. J Am Coll Cardiol (2015) 0.90
Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial. Am J Public Health (2010) 0.90
Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial. Diabetes Care (2014) 0.88
High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. Am J Med Sci (2010) 0.85
Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Obesity (Silver Spring) (2009) 0.82
Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care (2013) 0.82
Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clin J Am Soc Nephrol (2013) 0.80
Normal-Weight Central Obesity and Mortality Risk in Older Adults With Coronary Artery Disease. Mayo Clin Proc (2016) 0.79
Sex, clinical symptoms, and angiographic findings in patients with diabetes mellitus and coronary artery disease (from the Bypass Angioplasty Revascularization Investigation [BARI] 2 Diabetes trial). Am J Cardiol (2011) 0.79
Race/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Am J Cardiol (2013) 0.78
Appropriate revascularization in stable angina: lessons from the BARI 2D trial. Can J Cardiol (2014) 0.78
Left atrial size, chemosensitivity, and central sleep apnea in heart failure. Chest (2014) 0.77
Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care (2013) 0.77
Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis. J Diabetes Complications (2013) 0.77
The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol (2011) 0.75
Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Educ (2010) 0.75
Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events. J Am Coll Cardiol (2016) 0.75